Previous 10 | Next 10 |
Geographic atrophy is a progressive, irreversible retinal degenerative disease that can lead to blindness, with no currently approved treatments NGM621 is a monoclonal antibody against complement C3, a protein implicated in the pathophysiology of geographic atrophy, and is engineered ...
NGM Biopharmaceuticals (NGM) has dosed the first patient in a Phase 1/2 study to evaluate the efficacy, safety and pharmacokinetics/pharmacodynamics and and recommended Phase 2 dose of NGM707 when given alone or in combination with Keytruda (pembrolizumab). The Phase 1 portion (n=60) of the s...
--NGM707, a ILT2/ILT4 dual antagonistic antibody, is engineered to reverse myeloid suppression with the goal of improving patient immune responses to tumors-- --Study to evaluate potential of NGM707 in patients with tumor types with elevated expression of ILT2 and ILT4 as a mono...
Merck and NGM will continue their research, discovery and development collaboration with a narrower scope, focused primarily on retinal and cardiovascular and metabolic (CVM) targets of interest to Merck Merck will continue to advance MK-3655, an FGFR1c/KLB agonistic antibody, curre...
SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, w...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks inched higher Friday to finish in the green for the week, as optimism over the post-pandemic U.S. economic recovery drove the investme...
NEW YORK, NY / May 27, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating potential securities violations and breach of fiduciary duty claims against NGM Biopharmaceuticals, Inc. (NASDAQ:NGM). On May 24, 2021, NGM Biopharmaceutical...
For clinical-stage biotech companies, trial results are critical. On Monday, NGM Biopharmaceuticals (NASDAQ: NGM) reported very disappointing results from an investigative hepatitis drug and was summarily punished by investors, who drove the stock's price down by 41%. NGM's disc...
With a loss of more than a third in value so far, NGM Biopharmaceuticals ([[NGM]] -40.1%) is likely to post its biggest one-day loss after announcing its candidate for non-alcoholic steatohepatitis ((NASH)), aldafermin failed to meet the primary endpoint in a Phase 2/3 trial.Highlighting...
Gainers: Scopus BioPharma (SCPS) +97%.MMA Capital (MMAC) +58%.Aptorum (APM) +37%.Creative Realities (CREX) +33%.Obalon Therapeutics (OBLN) +30%.Regional Health Properties (RHE) +24%.Taiwan Liposome (TLC) +21%.Virgin Galactic (SPCE) +19%.Verastem (VSTM) +18%.Veritiv (VRTV) +17%.Loser...
News, Short Squeeze, Breakout and More Instantly...
NGM Biopharmaceuticals Inc. Company Name:
NGM Stock Symbol:
NYSE Market:
NGM Biopharmaceuticals Inc. Website:
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongo...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 202...